Objective-Extracellular matrix proteinases are implicated in the pathogenesis of calcific aortic valve disease. The ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) enzyme is secreted, matrix-associated metalloendopeptidase, capable of degrading extracellular matrix proteins, particularly matrilin 2. We sought to determine the role of the ADAMTS5/matrilin 2 axis in mediating the phenotype transition of valvular interstitial cells (VICs) associated with calcific aortic valve disease. Approach and Results-Levels of ADAMTS5, matrilin 2, and α-SMA (α-smooth muscle actin) were evaluated in calcified and normal human aortic valve tissues and VICs. Calcified aortic valves have reduced levels of ADAMTS5 and higher levels of matrilin 2 and α-SMA. Treatment of normal VICs with soluble matrilin 2 caused an increase in α-SMA level through Toll-like receptors 2 and 4, which was accompanied by upregulation of runt-related transcription factor 2 and alkaline phosphatase. In addition, ADAMTS5 knockdown in normal VICs enhanced the effect of matrilin 2. Matrilin 2 activated nuclear factor (NF) κB and NF of activated T cells complex 1 and induced the interaction of these 2 NFs. Inhibition of either NF-κB or NF of activated T cells complex 1 suppressed matrilin 2's effect on VIC phenotype change. Knockdown of α-SMA reduced and overexpression of α-SMA enhanced the expression of pro-osteogenic factors and calcium deposit formation in human VICs.
C alcific aortic valve disease (CAVD) is the most common valvular heart disease in the Western countries and increasingly affects the elderly. Approximately 2.8% of people >75 years old have aortic valve calcification, and 25% of adults >65 years of age have aortic valve sclerosis. 1 Currently, there is no effective pharmacological therapy for CAVD other than surgical or interventional valve replacement.
In the past decade, increasing evidence suggests that aortic valve calcification is a regulated pathological process mediated by the phenotype changes of valvular interstitial cells (VICs), the most abundant cell type in valve tissue, and chronic stresses are thought to cause prolonged activation of VICs, which may result in myofibroblastic-and osteoblastlike phenotypic transitions. 2, 3 Metalloproteinases, including matrix metalloproteinases, a disintegrin and metalloproteinase, or ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), play pivotal roles in cardiovascular remodeling by degrading matrix or nonmatrix substrates. 4, 5 In contrast to the extensive investigation of metalloproteinases in valvular remodeling, little is known about their role in valvular calcification. Previous study demonstrated that altered proteoglycan cleavage in ADAMTS5-deficient mice results in myxomatous cardiac valves, 6 suggesting a potential role of ADAMTS5 in congenital valve formation. However, the role of ADAMTS5 in CAVD has not been investigated. Matrilin 2 is a novel member of filament-forming oligomeric adaptor protein family that is involved in the development and homeostasis of the extracellular matrix (ECM) network. The levels of soluble matrilin 2 are remarkably increased during liver cirrhosis, osteoarthritis, and other inflammation-associated diseases. 7, 8 Besides its role in modulating ECM network, matrilin 2 induces a proinflammatory response in macrophages/microglia via TLR (Toll-like receptor)-mediated signaling pathways. 9 Our previous studies demonstrate that activating TLR2 or TLR4 elevates the pro-osteogenic activity in human VICs [10] [11] [12] and induces aortic valve lesions in mice. 13 It is likely that matrilin 2 induces VIC pro-osteogenic phenotypic transition through TLR4/2. Matrilin 2 is also identified as a shared gene in osteoblast progenitor cells and developing heart valves. 14 Recently, matrilin 2 is recognized as a substrate of ADAMTS5. 15 However, it remains unclear whether matrilin 2 accumulation contributes to the pathogenesis of valvular calcification.
We hypothesized that matrilin 2 accumulation as a result of relative ADAMTS5 deficiency contributes to valve calcification. The purpose of this study is to determine: (1) whether ADAMTS5 deficiency and matrilin 2 accumulation are associated with valvular calcification, (2) the effect of soluble matrilin 2 on VIC phenotype change and pro-osteogenic activity, and (3) the mechanism by which soluble matrilin 2 exerts its effect.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Calcified Human Aortic Valves Have Lower Levels of ADAMTS5 and Increased Levels of Matrilin 2
We analyzed gene expression profiles of VICs isolated from 5 normal aortic valves and VICs from noncalcified areas of 5 calcified aortic valves (valve donor demographics in Table I in the online-only Data Supplement) by gene microarray. The expressions of 377 genes were altered (fold change >1.3 and P<0.05 ; Tables II and III in the online-only Data Supplement) in VICs from calcified aortic valves in comparison to VICs from normal aortic valves. Among them, 20 displayed a change >2.0-fold ( Figure 1A ). ADAMTS5 was 1 of the 16 with >2.0-fold downregulation ( Figure 1A ). In contrast, levels of mRNA encoding TLR2, TLR4, matrilin 2, nuclear factor of activated T cells complex 1 (NFATc1), and nuclear factor (NF) κB were comparable between normal and diseased VICs.
To determine whether ADAMTS5 and matrilin 2 levels are altered in calcified aortic valves, we analyzed protein levels of ADAMTS5 and matrilin 2 in normal valve tissues and tissues from noncalcified areas of calcified aortic valves by immunoblotting and immunofluorescence staining. As shown in Figure 1B through 1D, calcified human aortic valves had reduced levels of ADAMTS5 in area without massive calcification, and matrilin 2 levels were markedly increased in the same area. Movat's pentachrome staining confirmed that ADAMTS5 primarily located in the fibrosa layer of normal aortic valve although it was also present in the ventricularis layer ( Figure I in the online-only Data Supplement).
VIC transition to myofibroblast is a critical step in valvular pathology associated with CAVD. 16 We examined myofibroblast by detecting its phenotypic biomarker, α-SMA (α-smooth muscle actin). The protein levels of α-SMA were higher in both tissues and cells from calcified human aortic valves than those from normal valves ( Figure 1B ; Figure  II in the online-only Data Supplement). Dual immunofluorescence staining and Von Kossa staining demonstrated that matrilin 2 accumulation was colocalized with α-SMA and calcification nodules in calcified aortic valves ( Figure 1D ). These data suggest that relative ADAMTS5 deficiency and associated matrilin 2 accumulation in calcified aortic valves may play a role in VIC myofibroblastic transition and aortic valve calcification.
Matrilin 2 Induces Myofibroblastic Transition and Upregulates Pro-Osteogenic Activity in VICs
To determine the role of the ADAMTS5/matrilin 2 axis in VIC phenotype change, VICs from normal human aortic valves were treated with recombinant matrilin 2 (0, 0.5, 1.0, and 2.0 μg/mL) for 48 hours. We then examined the expression of myofibroblastic markers, α-SMA and collagen I, as well as pro-osteogenic markers, Runx2 (runt-related transcription factor 2) and ALP (alkaline phosphatase). As shown in Figure 2A through 2C, stimulation of VICs with recombinant matrilin 2 resulted in a dose-dependent increase in protein levels of α-SMA, collagen I, Runx2, and ALP. Moreover, VICs exhibited abundant α-SMA-containing stress fibers after matrilin 2 treatment ( Figure 2B ). To determine whether matrilin 2 stimulation induces calcium deposition in VICs, we stimulated cells in a conditioning medium (growth medium supplemented with 10 mmol/L β-glycerophosphate, 10 nmol/L dexamethasone, 4 μg/mL cholecalciferol, and 8 mmol/L CaCl 2 ) with matrilin 2 for 21 days. Alizarin red S staining revealed that prolonged exposure to matrilin 2 in the conditioning medium significantly increased the formation of calcium deposits ( Figure 2D ). In contrast, the conditioning medium alone caused much lower levels of calcium deposit formation. Thus, matrilin 2 not only induces myofibroblastic transition but also elevates the pro-osteogenic activity in VICs. proinflammatory response in macrophage via the TLR signaling pathways. 9, 17 We examined whether TLR signaling is involved in matrilin 2-induced VIC phenotypic transition. VICs were treated with recombinant matrilin 2 of varying concentrations for different time periods. We observed that matrilin 2 increased cellular levels of TLR4 and TLR2 in dose-and time-dependent manners ( Figure 3A through 3C). To determine the role of these 2 innate immune receptors in mediating the effect of matrilin 2, we applied small interfering RNAs to knock down TLR4 and TLR2 ( Figure  3D ). Matrlin 2-induced upregulation of α-SMA and collagen I was inhibited by knockdown of either TLR4 or TLR2 ( Figure 3E) . Similarly, the levels of pro-osteogenic factors Runx2 and ALP were also reduced by knockdown of TLR4 or TLR2 ( Figure 3F ). In addition, neutralizing antibody against TLR4 or TLR2 also reduced the effect of matrilin 2 on the expression of α-SMA, Runx2, and ALP ( Figure III in the online-only Data Supplement). Therefore, matrilin 2 upregulates TLR4 and TLR2, and VIC phenotypic transition induced by matrilin 2 is mediated by these 2 innate immunoreceptors.
Matrilin 2 Induces VIC Phenotypic Transition Through TLR4 and TLR2
NF-κB Plays an Important Role in Mediating Matrilin 2-Induced VIC Phenotypic Transition
To identify the signaling pathway involved in mediating the response to matrilin 2, we examined NF-κB activation. We observed a marked increase in NF-κB p65 phosphorylation after matrilin 2 treatment, reaching a maximum after 2 hours ( Figure 4A ). Phosphorylation of NF-κB p65 was inhibited by neutralizing antibodies against TLR4 and TLR2 ( Figure 4B ). Furthermore, immunofluorescence staining confirmed intranuclear translocation of NF-κB p65 after matrilin 2 treatment and the inhibitory effect of TLR4 and TLR2 blockades on NF-κB p65 translocation ( Figure 4C ).
We applied Bay11-7082, a specific inhibitor of NF-κB, to verify the role of NF-κB activation in matrilin 2-induced VIC phenotypic transition. As shown in Figure 4D , inhibition of NF-κB significantly reduced the expression of α-SMA after matrilin 2 stimulation. Similar reduction was observed in pro-osteogenic markers Runx2 and ALP ( Figure 4E ). Furthermore, NF-κB inhibition attenuated calcium deposition in VICs exposed to matrilin 2 for a prolonged period in the conditioning medium ( Figure 4F ). Collectively, these protein levels were significantly lower, whereas the protein levels of matrilin 2 and α-SMA were higher. Mean±SE; n=6 per group; *P<0.05 vs normal. C, Representative images of immunofluorescence staining show ADAMTS5 (red) in normal and calcified human aortic valve tissues. Alexa 488-tagged wheat germ agglutinin (WGA) was used to outline plasma membrane (green). DAPI (4′, 6-diamidino-2-phenylindole) was used for nuclear counterstaining (blue). Original magnification, ×40 objective. D, Representative images of dual immunofluorescence staining of matrilin 2 (red) and α-SMA (green) and Von Kossa staining in normal and calcified human aortic valve tissues show that matrilin 2 was colocalized with α-SMA and was present in areas surrounding calcification nodule in calcified aortic valves. Original magnification, ×40 objective. Ao indicates the aortic side; and V, ventricular side of the valve leaflets.
results reveal that TLR-dependent NF-κB signaling plays an important role in matrilin 2-induced VIC phenotypic transition.
NFATc1 Is Involved in VIC Phenotypic Change Induced by Matrilin 2
NFATc1 is a transcription factor, and its level is found to correlate with osterix and Runx2 levels in calcified human aortic valves. 18 It has been reported that TLR2 modulates osteoclastogenesis and upregulates NFATc1. 19 We examined the effect of matrilin 2 on NFATc1 level and activity. Matrilin 2 evoked an increase in NFATc1 expression in dose-and time-dependent fashions ( Figure 5A and 5B). Immunofluorescence analysis confirmed increased NFATc1 levels and intranuclear translocation of this nuclear factor after matrilin 2 stimulation ( Figure 5C ). Neutralization antibodies against TLR4 or TLR2 repressed the increase in NFATc1 ( Figure 5D ). To investigate whether NFATc1 activation is involved in VIC phenotypic transition, we used both lentiviral NFATc1 small hairpin RNA (shRNA) and a specific inhibition peptide, VIVIT. As shown in Figure 5E , lentiviral NFATc1 shRNA reduced the levels of NFATc1. Inhibition of NFATc1 by shRNA or VIVIT markedly suppressed matrilin 2-induced upregulation of α-SMA, Runx2, and ALP ( Figure 5F ; Figure IV in the online-only Data Supplement). Moreover, NFATc1 knockdown attenuated VIC mineralization induced by prolonged stimulation with matrilin 2 in the conditioning medium ( Figure 5G ). Together, these data show that NFATc1 is also involved in the mechanism of VIC phenotypic change induced by matrilin 2.
NF-κB Modulates NFATc1 Activation
Previous studies indicate that NF-κB and NFATc1 interact with each other and that NF-κB modulates the expression of NFATc1 in lymphocyte, macrophage, and cardiomyocyte. [20] [21] [22] To examine whether NFATc1 is downstream of NF-κB in matrilin 2-induced cellular signaling in human VICs, we pre-treated VICs with 2 distinct NF-κB inhibitors, Bay 11-7082 and SN50, before matrilin 2 stimulation. However, inhibition of NF-κB with either inhibitor had no effect on the upregulation of NFATc1 protein levels by matrilin 2 ( Figure 6A and 6B). Interestingly, inhibition of NF-κB suppressed matrilin 2-induced NFATc1 activation ( Figure 6C ). Then, we examined whether NFATc1 interacts with NF-κB in human VICs using coimmunoprecipitation. The results in Figure 6D show that NFATc1 is coimmunoprecipitated with NF-κB p65. Conversely, immunoprecipitation of NFATc1 resulted in the coprecipitation of NF-κB p65. Moreover, enhanced binding of the 2 transcription factors was observed in cells exposed to matrilin 2 ( Figure 6D ). A, VICs from normal human aortic valves were treated with recombinant matrilin 2 for 48 h. Matrilin 2-induced myofibroblastic transition in VICs, as characterized by enhanced expression of α-SMA (α-smooth muscle actin) and collagen I. B, VICs had greater amounts of α-SMA-containing stress fibers (green) after matrilin 2 stimulation. DAPI (4′, 6-diamidino-2-phenylindole) was used for nucleus counterstaining (blue). C, Matrilin 2 increased the expression of Runx2 (runt-related transcription factor 2) and ALP (alkaline phosphatase) in VICs in a dose-dependent manner. D, VICs were incubated with matrilin 2 (2.0 μg/mL) for 21 d in conditioning medium (containing 10 mmol/L β-glycerophosphate, 10 nmol/L dexamethasone, 4.0 μg/mL cholecalciferol, and 8 mmol/L CaCl 2 ) to examine calcium deposit formation. Images of Alizarin red S staining (×10 objective for the high power images) and spectrophotometric analysis show that prolonged stimulation with matrilin 2 increased calcium deposit formation. Mean±SE; n=5 separate experiments using distinct cell isolates; *P<0.05 vs control.
Therefore, NF-κB seems to interact with NFATc1 to modulate its activity.
ADAMTS5 Deficiency Enhances the Effect of Matrilin 2 on VIC Phenotypic Transition
We treated cells from calcified aortic valves with recombinant human ADAMTS5 protein and found that basal levels of α-SMA, Runx2, and ALP in VICs of calcified aortic valves were markedly decreased by this treatment ( Figure 7A ). In VICs from normal aortic valves, recombinant ADAMTS5 also attenuated the upregulation of α-SMA, Runx2, and ALP induced by matrilin 2 ( Figure 7B ). In addition, we performed loss-of-function experiments to determine whether ADAMTS5 deficiency augments the effect of matrilin 2 on normal VICs. As shown in Figure 7C , specific small interfering RNA reduced the levels of ADAMTS5. ADAMTS5 knockdown resulted in an increase in α-SMA, Runx2, and ALP in VICs of normal aortic valves ( Figure 7D and 7E) . Interestingly, a combination of ADAMTS5 knockdown and matrilin 2 stimulation resulted in significantly higher levels of α-SMA, Runx2, and ALP expressions as compared with matrilin 2 stimulation alone ( Figure 7D and 7E) . Thus, relative ADAMTS5 deficiency elevates the expressions of α-SMA, Runx2, and ALP in human VICs and augments the effect of matrilin 2.
Myofibroblastic Transition Elevates Pro-Osteogenic Activity in VICs
Previous studies suggest a link between myofibroblasts and calcium nodule formation in aortic valves. 23 However, it remains unclear whether myofibroblasts are the so-called osteoblast-like cells. Immunofluorescence microscopy revealed that myofibroblastic biomarker α-SMA and proosteogenic biomarker Runx2 were colocalized in VICs from calcified aortic valves as well as in normal VICs exposed to matrilin 2 for 48 hours ( Figure 8A and 8B). To determine whether myofibroblast have elevated pro-osteogenic activity, VICs were transduced for 72 or 96 hours with lentivirus expressing α-SMA. The levels of α-SMA were markedly increased by overexpression ( Figure V in the online-only Data Supplement). Overexpression of α-SMA in VICs from normal aortic valves resulted in the upregulation of Runx2 and ALP ( Figure 8C ). In addition, VICs that overexpress α-SMA exhibited greater calcium deposition ( Figure 8D ). Thus, it seems that myofibroblasts are osteoblast-like cells in human aortic valves.
To determine whether overexpression of α-SMA (myofibroblastic transition) is responsible for the elevation of pro-osteogenic activity, we transduced cells with lentiviral shRNA to inhibit α-SMA expression. As shown in Figure 8E , matrilin 2 failed to increase the protein levels of α-SMA in Figure 3 . Toll-like receptors (TLRs) 4 and 2 mediate matrilin 2-induced valvular interstitial cell (VIC) phenotypic transition. A-C, VICs from normal human aortic valves were treated with recombinant matrilin 2 (2.0 μg/ mL) for 48 h. Representative immunoblots and densitometric data show that matrilin 2 increased the levels of TLR4 and TLR2 in dose-and time-dependent manners. D, VICs were treated with TLR4 small interfering RNA (siRNA; 100 nmol/L) and TLR2 siRNA (100 nmol/L) for 72 h. TLR4 siRNA and TLR2 siRNA reduced the levels of TLR4 and TLR2, respectively. E and F, VICs with knockdown of TLR4 or TLR2 were treated with matrilin 2 (2.0 μg/mL) for 48 h. Knockdown of either TLR4 or TLR2 suppressed the upregulation of α-SMA (α-smooth muscle actin), collagen I, Runx2 (runt-related transcription factor 2), and ALP (alkaline phosphatase) by matrilin 2. Mean±SE; n=4 separate experiments using distinct cell isolates; *P<0.05 vs control; #P<0.05 vs matrilin 2+control siRNA. July 2017
VICs transduced with lentiviral α-SMA shRNA. Furthermore, the expression of Runx2 and ALP in response to matrilin 2 stimulation was greatly reduced in VICs transduced with lentiviral α-SMA shRNA compared with cells transduced with scramble shRNA (Figure 8F ). More importantly, α-SMA knockdown significantly reduced calcium deposit formation after prolonged stimulation with matrilin 2 in the conditioning medium ( Figure 8G ). Taken together, these results suggest that matrilin 2 induces myofibroblastic transition to elevate the pro-osteogenic activity in VICs and that myofibroblasts are osteoblast-like cells in human aortic valves.
Discussion
Numerous studies support the concept that valvular calcification is an active process involving multiple mechanisms, including abnormal calcium or phosphate metabolism, valvular inflammation, pro-osteogenic reprogramming of VICs, and ECM remodeling. 16 Currently, little is known about ADAMTS5 involvement in valvular calcification. In this study, we identified relative ADAMTS5 deficiency and matrilin 2 accumulation in calcified human aortic valves. Stimulation of VICs from normal human aortic valves with soluble matrilin 2 induces myofibroblastic and osteoblast-like changes through Phosphorylation of NF-κB p65 occurred mainly at 1 and 2 h after matrilin 2 treatment. B and C, VICs were treated with matrilin 2 (2.0 μg/mL) for 2 h in the presence or absence of neutralizing antibodies against TLR4 (Toll-like receptor 4; 10 μg/mL) and TLR2 (10 μg/mL). Immunoblots show that neutralizing antibodies against TLR4 and TLR2 suppressed NF-κB p65 phosphorylation after matrilin 2 stimulation. Representative images of immunofluorescence staining of NF-κB p65 (red) show that NF-κB p65 intranuclear translocation induced by matrilin 2 was reduced by neutralizing antibodies against TLR4 and TLR2. Alexa 488-tagged wheat germ agglutinin (WGA) was used to outline cells (green). DAPI (4′, 6-diamidino-2-phenylindole) was used for nuclear counterstaining (blue). Original magnification, ×40 objective. D and E, NF-κB inhibitor, Bay 11-7082 (10 μmol/L), reduced the levels of α-SMA (α-smooth muscle actin), Runx2 (runtrelated transcription factor 2), and ALP (alkaline phosphatase) in cells exposed to matrilin 2 (2.0 μg/mL) for 48 h. F, To examine calcium deposit formation, VICs in the conditioning medium were treated with matrilin 2 (2.0 μg/mL) for 21 d in the presence or absence of Bay 11-7082 (10 μmol/L). Alizarin red S staining shows that NF-κB inhibition reduced the formation of calcium deposits in cells treated with matrilin 2 (×10 objective for the high power image). Mean±SE; n=4 separate experiments using distinct cell isolates; *P<0.05 vs control; #P<0.05 vs matrilin 2+nonimmune IgG or matrilin 2+dimethyl sulfoxide (DMSO). a mechanism dependent of TLR4 and TLR2. Treatment of VICs of calcified aortic valves with recombinant ADAMTS5 reduces levels of myofibroblastic and pro-osteogenic biomarkers. Conversely, knockdown of ADAMTS5 augments the upregulation of myofibroblastic and pro-osteogenic biomarkers by matrilin 2 in normal VICs. Mechanistically, NF-κB and NFATc1 signaling pathways play important roles in mediating the effect of matrilin 2 on VIC phenotype transition, and NF-κB modulates NFATc1 activity through molecular interaction. Furthermore, we found that myofibroblastic transition is required for the elevated pro-osteogenic activity in VICs exposed to matrilin 2. This study provides the initial evidence that relative ADAMTS5 deficiency in human aortic valves elevates VIC pro-osteogenic activity through matrilin 2-mediated cell phenotypic transition.
ADAMTS family is comprised 19 secreted, ECMdegrading enzymes that can be subgrouped on the basis of their substrates. 24 Although much interest has focused on matrix metalloproteinases, pathobiological role of ADAMTS has recently been recognized. Aberrant expression or malfunction of ADAMTS members have been implicated in several conditions, such as arthritis, cancer, and atherosclerosis. [25] [26] [27] Previous studies have demonstrated that ADAMTS7, through processing of cartilage oligomeric matrix protein, mediates vascular smooth muscle cell migration and neointimal formation in response to vascular injury. 28, 29 Matrilins appear as oligomeric adaptor proteins and mediate the interaction between collagen fibrils and other ECM components to form supramolecular networks. Among the 4 family members, matrilin 2, a substrate of ADAMTS5, is identified in cartilage and many other types of connective tissue. 8 Currently, it is unknown whether the ADAMTS5/matrilin 2 axis is involved in the mechanism of valvular calcification. 
ADAMTS5/Matrilin 2 Axis Plays an Important Role in VIC Phenotypic Transitions
We revealed that the levels of ADAMTS5 mRNA and protein are lower in VICs and valvular tissue of patients with CAVD. Interestingly, ADAMTS5 protein is primarily, but not exclusively, localized in the aortic side of normal aortic valves. Interestingly, significantly lower levels of ADAMTS5 are detected in calcified aortic valves. The localization pattern of ADAMTS5 indicates a role of ADAMTS5 in valvular calcification because calcification frequently begins on the aortic side of the valve leaflets. [30] [31] [32] In correlation to relative ADAMTS5 deficiency, matrilin 2 levels are markedly higher in the same areas of calcified aortic valves. Because matrilin 2 is a substrate of ADAMTS5, matrilin 2 accumulation in calcified aortic valves is also indicative for ADAMTS5 deficiency. It seems that lower levels of ADAMTS5 in calcified aortic valves result in matrilin 2 accumulation. More importantly, elevated levels of matrilin 2 are colocalized with α-SMA and the calcification nodules in calcified aortic valves.
Previous studies found that VICs from calcified aortic valves produce higher levels of α-SMA and pro-osteogenic biomarkers, including Runx2 and ALP. 12, 33 However, the underlying molecular mechanism is incompletely understood. We observed that ADAMTS5 deficiency and matrilin 2 accumulation are associated with overexpression of myofibroblastic and pro-osteogenic biomarkers in calcified aortic valves. Four lines of evidence from this study indicate a link between the ADAMTS5/matrilin 2 axis and the production of α-SMA and pro-osteogenic biomarkers in VICs. First, lower levels of ADAMTS5 and elevated levels of matrilin 2 are colocalized with α-SMA and calcification nodules in calcified aortic valves. This provided in vivo evidence that the ADAMTS5/matrilin 2 axis is associated with aortic valve calcification. Second, recombinant ADAMTS5 downregulates the levels of myofibroblastic and pro-osteogenic biomarkers in VICs from calcified aortic valves as well as in matrilin 2-stimulated VICs from normal aortic valves. Third, soluble matrilin 2 upregulates the expression of α-SMA, collagen I, Runx2, and ALP in normal VICs cultured in growth medium, and prolonged treatment with matrilin 2 in the conditioning medium (with higher calcium and phosphate concentrations) promotes calcium deposit formation. Last, knockdown of ADAMTS5 augments the expression of myofibroblastic and pro-osteogenic biomarkers in VICs exposed to matrilin 2. Collectively, these data demonstrate that matrilin 2 is capable of upregulating the expression of osteogenic Figure 6 . Nuclear factor (NF) κB controls the activation of nuclear factor of activated T cells complex 1 (NFATc1). A-C, Valvular interstitial cells from normal aortic valves were treated with Bay11-7082 (10 μmol/L) or SN50 (100 μg/mL) 1 h before matrilin 2 (2.0 μg/ mL) stimulation for 48 h. Immunoblots and densitometric data show that either Bay11-7082 or SN50 failed to suppress matrilin 2-induced expression of NFATc1 (A and B) . NFATc1 activity data show that inhibition of NF-κB by Bay11-7082 or SN50 attenuated NFATc1 activation induced by matrilin 2 (C). D, Immunoblots for NF-κB p65 and NFATc1 after immunoprecipitation with anti-p65 antibody, anti-NFATc1 antibody, or nonimmune IgG demonstrate interaction of these 2 nuclear factors. Mean±SE; n=4 separate experiments using distinct cell isolates; *P<0.05 vs control; #P<0.05 vs matrilin 2+dimethyl sulfoxide (DMSO) or matrilin 2+SN50M; IB indicates immunoblotting; IP, immunoprecipitation; and NS, nonsignificant.
biomarkers (Runx2 and ALP) in human VICs independent of the pro-osteogenic medium and promoting calcium deposit formation in the presence of the pro-osteogenic medium. Matrilin 2 accumulation associated with relative ADAMTS5 deficiency seems to be responsible, at least in part, for the upregulation of production of biomarkers for myofibroblastic and osteoblastic-like cells in human VICs. Therefore, it is likely that the ADAMTS5/matrilin 2 axis contributes to the mechanism of VIC phenotypic transition associated with CAVD.
However, myxomatous valve disease is found in ADAMTS5 −/− mice. 6 This distinct pathology may be because of total absence of ADAMTS5, rather than a relative deficiency, and the impact of genetic defect on valve development. The discrepancy between our observation and the study on ADAMTS5 −/− mice may be explained by the difference between mice and human, as well as the difference between in vivo valve development abnormalities and isolated VICs from diseased aortic valve tissue that has complex pathology. It should also be noted that ADAMTS5 deficiency is likely a contributing factor for CAVD that involves multifactorial pathogenesis.
NF-κB and NFATc1 Signaling Pathways Mediate the Effect of Matrilin 2
Several ECM proteins, such as fibronectin, hyaluronanderived oligosaccharides, lumican, and biglycan, are now recognized as endogenous ligands of the pattern recognition receptors. 6, 33, 34 A previous study has shown that matrilin 2 activates proinflammatory signaling pathways in macrophages via TLRs. 9 In this study, we found increased expression of both TLR4 and TLR2 in normal human VICs after matrilin 2 stimulation. The potency of matrilin 2 for the induction of α-SMA, collagen I, Runx2, and ALP expression is attenuated by knockdown of TLR4 or TLR2. These observations suggest that both TLR2 and TLR4 are involved in mediating the responses to matrilin 2. It is possible that TLR2 and TLR4 interact. Namely, TLR2 activation affects TLR4 activity and verse versa. Alternatively, these 2 innate immune receptors may dimerize or synergize in response to matrilin 2 stimulation. In this regard, interaction between TLR2 and TLR4 has been reported. 35 Nevertheless, matrilin 2 induces phenotypic transition in human VICs through a TLR-dependent mechanism. This finding is consistent with our previous work that Immunoblots and densitometric data show that ADAMTS5 decreased the baseline levels of α-SMA (α-smooth muscle actin), Runx2 (runt-related transcription factor 2), and ALP (alkaline phosphatase). B, VICs from normal aortic valves were treated with rhADAMTS5 (5.0 µg/mL) 1 h before matrilin 2 (2.0 μg/mL) stimulation for 48 h. ADAMTS5 attenuated the upregulation of α-SMA, Runx2, and ALP by matrilin 2. C, ADAMTS5 small interfering RNA (siRNA) reduced ADAMTS5 levels in VICs from normal aortic valves. D and E, VICs from normal aortic valves were transfected with ADAMTS5 siRNA 72 h before matrilin 2 stimulation for 48 h. Immunoblots and densitometric data show that ADAMTS5 knockdown augmented the upregulation of α-SMA, Runx2, and ALP by matrilin 2. Mean±SE; n=4 separate experiments using distinct cell isolates; *P<0.05 vs untreated control and control siRNA-treated; #P<0.05 vs matrilin 2 alone or matrilin 2+control siRNA.
Figure 8. Myofibroblastic transition elevates pro-osteogenic activity in valvular interstitial cells (VICs).
A, Dual immunofluorescence staining was applied to localize α-SMA (α-smooth muscle actin; green) and Runx2 (runt-related transcription factor 2; red) in VICs from calcified valves. These 2 proteins were identified in the same cells in the absence of a stimulation. Original magnification, ×40 objective. B, In VICs from normal aortic valves, α-SMA and Runx2 were identified by dual immunofluorescence staining after stimulation with matrilin 2 (2.0 μg/mL) for 48 h. Original magnification, ×40 objective. C, VICs from normal aortic valves were transduced with lentivirus expressing α-SMA for 96 h. Immunoblots show that α-SMA overexpression increased the protein levels of Runx2 and ALP (alkaline phosphatase). n=3 separated experiments using distinct cell isolates. D, VICs from normal aortic valves were transduced with lentivirus expressing α-SMA for 96 h and then incubated in the conditioning medium for 21 d to examine calcium deposit formation. Alizarin red S staining shows that α-SMA overexpression increased calcium deposition. Mean±SE; n=4 separated experiments using distinct cell isolates; *P<0.05 vs vector control. E and F, VICs were transduced with lentiviral α-SMA shRNA 72 h before matrilin 2 (2.0 μg/mL) stimulation for 48 h. Lentiviral α-SMA shRNA reduced α-SMA levels and abrogated the upregulation of Runx2 and ALP by martrilin 2. Mean±SE; n=4 separated experiments using distinct cell isolates; *P<0.05 vs control; #P<0.05 vs matrilin 2+control shRNA. G, VICs from normal aortic valves were pre-treated with lentiviral α-SMA shRNA or lentiviral control shRNA and then treated with matrilin 2 (2.0 μg/mL) for 21 d in the conditioning medium to examine calcium deposit formation. Images of Alizarin red S staining and spectrophotometric data show that α-SMA knockdown reduced calcium deposition in VICs after prolonged matrilin 2 stimulation. Mean±SE; n=4 separated experiments using distinct cell isolates; *P<0.05 vs control; #P<0.05 vs matrilin 2+control shRNA; vector, lentiviral control vector.
VICs isolated from calcified aortic valves express greater levels of TLR4 and TLR2 than normal VICs, and stimulation of TLR4 and TLR2 in human VICs promotes Runx2 expression and elevates ALP activity. 11 Activation of TLR4 or TLR2 initiates several downstream signaling cascades. The data revealed that matrilin 2 induces the activation of NF-κB and NFATc1 in human VICs through TLR4 and TLR2. Our previous study revealed that NF-κB signaling elevates the pro-osteogenic activity in human VICs exposed to bacterial or endogenous agents. 12 Similarly, matrilin 2-induced VIC phenotypic transition involves TLR4/2-mediated NF-κB activation because the effects of matrilin 2 are attenuated by inhibition of IκB kinase with Bay11-7082. More interestingly, the mechanism of matrilin 2 action on human VICs also involves upregulation and activation of NFATc1. NFATc1 is a nuclear factor originally described in immune cells, and it has been implicated in vascular remodeling. 36 Previous studies found that calcineurin/NFATc1 upregulates Runx2 expression in osteoblasts in response to mechanical stretching. 37 Although NFATc1 has been identified in calcified aortic valves, its role in VIC phenotypic transition and valvular calcification remains unknown. Our data show that matrilin 2 increases NFATc1 levels and activity in a TLR4/2-dependent fashion. Knockdown of NFATc1 essentially abrogates the upregulation of α-SMA, Runx2, and ALP, as well as calcium deposition in VICs exposed to matrilin 2. These data highlight a novel role of NFATc1 in human VIC transition to myofibroblasts and osteoblast-like cells.
Although endothelial cells and immune cells are involved in the pathogenesis of aortic valve calcification, VICs, as the major cell type of aortic valve, and their phenotype transition play a critical role in the development and progression of aortic valve calcification. 38 Thus, it is important to investigate the mechanism underlying their phenotypic transition. Our data reveal that human VIC express TLR2, TLR4, and NFATc1 and that matrilin 2 induces phenotypic transition in human VICs through a TLR-NF-κB/NFATc1 cascade. Thus, this study identified an endogenous factor and the signaling mechanism by which this factor modulates VIC phenotype transition.
It has been reported that NF-κB and NFATc1 interact, and NF-κB modulates the expression of NFATc1 in several cell types. [20] [21] [22] Whereas inhibition of NF-κB has no effect on NFATc1 upregulation by matrilin 2 in human VICs, inhibition of NF-κB suppresses matrilin 2-induced activation of NFATc1. Furthermore, we found that p65 interacts with NFATc1 after matrilin 2 stimulation in human VICs. Therefore, NF-κB and NFATc1 interact and coordinately mediate VIC myofibroblastic and osteoblast-like transition.
Myofibroblastic Transition Is Required for Matrilin 2-Induced Elevation of Pro-Osteogenic Activity
VICs comprise a diverse and highly plastic population of resident cells responsible for remodeling and integrity of ECM. In normal aortic valves, VICs are mostly quiescent fibroblast-like cells, and myofibroblasts only account for a small proportion. In calcified valves, however, the VIC population shifts to be mainly activated myofibroblasts displaying increased α-SMA expression, contractility, and collagen production. 2 Thus, the appearance of increased myofibroblast density is considered as an early pathobiological event in CAVD. 39 Another major pathogenic phenotype present in calcified valves is the osteoblast-like cells that express osteoblast biomarkers, such as Runx2, osterix, as well as ALP, and are responsible for the active deposition of calcium. 40 Like myofibroblasts, these osteoblast-like cells might also be derived from VICs in response to pathological cues. However, it remains unclear whether the osteoblast-like cells and myofibroblasts are distinct cells or the same identity. Soluble matrilin 2 induces the expression of biomarkers for both myofibroblasts and osteoblast-like cells in VICs. Elevated levels of Runx2 and α-SMA are colocalized in a population of normal VICs exposed to matrilin 2, and coappearance of increased α-SMA levels and greater Runx2 expression in the same cell is characteristic for a population of VICs of calcified aortic valves. In addition, VICs that overexpress α-SMA exhibited increased expression of Runx2 and ALP, as well as calcium deposition. Furthermore, by application of a knockdown approach, we demonstrated that upregulation of α-SMA expression is required for matrilin 2-induced expression of pro-osteogenic biomarkers (Runx2 and ALP) and calcium deposit formation. These data led us to speculate that the osteoblast-like phenotypic transition involves a fibroblast-myofibroblast-osteoblast process. In this regard, conflicting findings have been reported. A previous study found that overexpression of α-SMA increases VIC contractility and formation of calcification nodules in vitro. 23 An in vivo study also demonstrated that valvular myofibroblasts exhibit osteoblastic activity in the early stage of aortic valve stenosis. 41 However, decreased Runx2 expression is associated with enhanced α-SMA expression in Notch1-deficient VICs. 42 Although further work is needed to establish the relationship of myofibroblasts and the osteoblast-like cells in calcified aortic valves, our findings suggest that myofibroblasts with greater levels of osteogenic biomarkers are either the osteoblast-like cells or in the intermediate stage of transition to osteoblasts.
In summary, this study demonstrates a novel role of the ADAMTS5/matrilin 2 axis in modulating the pathological phenotype change in human VICs. Relative ADAMTS5 deficiency in calcified human aortic valves is associated with accumulation of matrilin 2. Matrilin 2 induces myofibroblastic transition and elevates pro-osteogenic activity in VICs via TLR2/4-dependent activation of NF-κB and NFATc1. Furthermore, myofibroblastic transition elevates VIC proosteogenic activity. The results of this study suggest that targeting the ADAMTS5/matrilin 2 axis may have therapeutic potential for suppression of VIC myofibroblastic transition and for prevention of CAVD progression.
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